Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III: UbLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

Trial Profile

Phase III: UbLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ublituximab (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ULTIMATE 2; ULTIMATE II
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 08 Mar 2024 According to TG Therapeutics, Inc media release, data from this study will be presented at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.
    • 20 Feb 2024 According to TG Therapeutics, Inc media release, the schedule of data presentations highlighting data from the ULTIMATE I and II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI(ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 29-March 2, 2024, in West Palm Beach, Florida.
    • 13 Oct 2023 Results of pooled analysis from ULTIMATE I and II , analyzing disease Activity Score and Disease Pathway Scores Measured Using the MSDA Test are Significantly Reduced Prior to the Week 48 Dose for Patients Treated with Ublituximab, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top